Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Alaunos Therapeutics received Nasdaq confirmation that it regained compliance with the stockholders’ equity requirement, closing the delisting matter. The November 10, 2026 hearing was canceled, and its common stock will continue trading on The Nasdaq Capital Market.
Alaunos Therapeutics believes it regained Nasdaq’s stockholders’ equity compliance after receiving approximately $350.0 million in gross financing proceeds; Nasdaq will continue monitoring ongoing compliance.
Alaunos Therapeutics, Inc. completed its acquisition of Velaris Therapeutics, Inc. on October 13, 2026 and agreed to sell securities for approximately $350 million, expected to close October 14, 2026, to fund Velaris programs, working capital and general corporate purposes.
Alaunos Therapeutics received Nasdaq notice that its securities were subject to delisting after failing to satisfy Nasdaq Listing Rule 5550(b)(1). On October 5, 2026, it planned to request a hearing, which would stay delisting action, while evaluating strategic alternatives.
Alaunos Therapeutics, Inc. closed a registered direct offering on September 21, 2026, selling 380,469 shares at $1.46 per share and 386,654 pre-funded warrants at $1.459 per warrant, generating net proceeds of approximately $915,400.50 for working capital.
